2023-08-21 11:56:10 ET
More on gene therapies
- Vertex Pharmaceuticals: Strategically Positioning For Future Success
- Vertex And CRISPR Therapeutics - Partners On Exa-cel - But Unequally Valued
- Crispr Therapeutics: Biotech To Watch With Regulatory Approvals Of Exa-Cel On Deck
- CRISPR Therapeutics upgraded to buy at Citi on near-term approvals
- bluebird bio's lovo-cel won't have FDA advisory panel meeting
- bluebird bio gains as BofA upgrades citing FDA nod for new gene therapy
- Compare metrics for BLUE to CRSP, VRTX
For further details see:
Vertex/CRISPR, bluebird sickle cell therapies could be cost-effective - ICER